Evidence map›Paper›PMID 36675313›Full record

ReviewInternational journal of molecular sciences2023

An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer.

Domenico Tierno, Gabriele Grassi, Fabrizio Zanconati, Marina Bortul, Bruna Scaggiante

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Domenico TiernoDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0003-0858-6192
Gabriele GrassiDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0001-9704-6651
Fabrizio ZanconatiDepartment of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, 34149 Trieste, Italy.
Marina BortulDepartment of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, 34149 Trieste, Italy.
Bruna ScaggianteDepartment of Life Sciences, University of Trieste, 34127 Trieste, Italy.ORCID 0000-0002-8662-138X
University of Trieste · IT

Funding

Lega Italiana per la Lotta contro i Tumori, Associazione Provinciale di Trieste-Italy dicembre 2022
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer due to its molecular heterogeneity and poor clinical outcomes. Analysis of circulating cell-free tumor nucleic acids (ctNAs) can improve our understanding of TNBC and provide efficient and non-invasive clinical biomarkers that may be representative of tumor heterogeneity. In this review, we summarize the potential of ctNAs to aid TNBC diagnosis and prognosis. For example, tumor fraction of circulating cell-free DNA (TFx) may be useful for molecular prognosis of TNBC: high TFx levels after neoadjuvant chemotherapy have been associated with shorter progression-free survival and relapse-free survival. Mutations and copy number variations of TP53 and PIK3CA/AKT genes in plasma may be important markers of TNBC onset, progression, metastasis, and for clinical follow-up. In contrast, the expression profile of circulating cell-free tumor non-coding RNAs (ctncRNAs) can be predictive of molecular subtypes of breast cancer and thus aid in the identification of TBNC. Finally, dysregulation of some circulating cell-free tumor miRNAs (miR17, miR19a, miR19b, miR25, miR93, miR105, miR199a) may have a predictive value for chemotherapy resistance. In conclusion, a growing number of efforts are highlighting the potential of ctNAs for future clinical applications in the diagnosis, prognosis, and follow-up of TNBC.

Indexed as

Cell-Free Nucleic AcidsCirculating MicroRNAMicroRNAsTriple Negative Breast NeoplasmsBiomarkers, TumorDNA Copy Number VariationsHumansNeoplasm Recurrence, LocalBiomarkers, TumorCell-Free Nucleic AcidsCirculating MicroRNAMicroRNAsMIRN105 microRNA, humanMIRN25 microRNA, humancirculating cell-free nucleic acidscirculating cell-free tumor DNAcirculating cell-free tumor lncRNAcirculating cell-free tumor miRNAliquid biopsyTNBC

Identifiers

PMID36675313
PMCPMC9864244
OpenAlexW4316672756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.